## **Erratum**

## Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

In the article by Hingorani et al. (Cancer Cell 4, pp. 437–450), there are several typographical errors in the text regarding the citation of the figures.

On page 441, the sentence "In many of the older mice, the pancreata contained extensive ductal lesions, and the acinar parenchyma was largely replaced by an intense stromal, or desmoplastic, reaction comprised of inflammatory cells, fibroblasts, and collagen deposition (Figures 2I–2K)" should instead refer to Figures 2I–2L.

Also on page 441, the sentence "Finally, we note that PanlNs expressed only low levels of *PDX-1*, which can nevertheless be discerned when compared to the lack of expression in surrounding acini (Figures 2G and 2H) and to normal ducts in control animals (Figure 2l)" should refer instead to Figure 3, and thus should read "Finally, we note that PanlNs expressed only low levels of *PDX-1*, which can nevertheless be discerned when compared to the lack of expression in surrounding acini (Figures 3G and 3H) and to normal ducts in control animals (Figure 3l)."

Sunil R. Hingorani,<sup>1,2</sup> Emanuel F. Petricoin III,<sup>3</sup> Anirban Maitra,<sup>4</sup> Vinodh Rajapakse,<sup>5</sup> Catrina King,<sup>2</sup> Michael A. Jacobetz,<sup>2</sup> Sally Ross,<sup>5</sup> Thomas P. Conrads,<sup>6</sup> Timothy D. Veenstra,<sup>6</sup> Ben A. Hitt,<sup>7</sup> Yoshiya Kawaguchi,<sup>8</sup> Don Johann,<sup>5</sup> Lance A. Liotta,<sup>5</sup> Howard C. Crawford,<sup>9</sup> Mary E. Putt,<sup>10</sup> Tyler Jacks,<sup>11</sup> Christopher V.E. Wright,<sup>8</sup> Ralph H. Hruban,<sup>4</sup> Andrew M. Lowy,<sup>12</sup> and David A. Tuveson<sup>1,2,\*</sup> <sup>1</sup>Department of Medicine

<sup>2</sup>Department of Cancer Biology

Abramson Family Cancer Research Institute, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania 19104

- <sup>3</sup>FDA-NCI Clinical Proteomics Program, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
- <sup>4</sup>Departments of Pathology and Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287
- <sup>5</sup>FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland 20892
- <sup>6</sup> National Cancer Institute Biomedical Proteomics Program, Analytical Chemistry Laboratory, Mass Spectrometry Center, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, Maryland 21702
- <sup>7</sup>Correlogic Systems, Inc., Bethesda, Maryland 20892
- <sup>8</sup> Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
- <sup>9</sup>Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, New York, 11794
- <sup>10</sup>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104
- <sup>11</sup>Department of Biology, Massachusetts Institute of Technology, and Howard Hughes Medical Institute, Center for Cancer Research, Cambridge, Massachusetts 02139
- <sup>12</sup>Department of Surgery, Division of Surgical Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45219
- \*Correspondence: tuvesond@mail.med.upenn.edu